The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In phase I studies of CT053, 24 patients received a dose ranging from 0.5 to 1.8 × 10^6 CT053 cells, and the ORR was 87.5%.
“In the phase I studies (NCT03302403, NCT03380039, NCT03716856), 24 patients received a dose ranging from 0.5 to 1.8 × 10^6 CT053 cells, the ORR was 87.5%, indicating a high rate of response to CT053 treatment, with 79.2% patients achieved CR (12.5%) or sCR (66.7%), demonstrating deep and durable responses, and the median follow-up time was 17.4 months, the mPFS was 18.8 months and the mDOR was 21.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [250]
The phase I trial results (page not provided) report that 24 patients received CT053 and that the overall response rate was 87.5%. The reported dose range was 0.5–1.8 × 10^8 cells, not 0.5–1.8 × 10^6 cells as claimed. (LLM, conf=0.94)
Experimental — accuracy not yet measuredIn these studies, 79.2% of patients achieved CR (12.5%) or sCR (66.7%).
“In the phase I studies (NCT03302403, NCT03380039, NCT03716856), 24 patients received a dose ranging from 0.5 to 1.8 × 10^6 CT053 cells, the ORR was 87.5%, indicating a high rate of response to CT053 treatment, with 79.2% patients achieved CR (12.5%) or sCR (66.7%), demonstrating deep and durable responses, and the median follow-up time was 17.4 months, the mPFS was 18.8 months and the mDOR was 21.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [250]
The median follow-up was 17.4 months, the mPFS was 18.8 months, and the mDOR was 21.8 months.
“In the phase I studies (NCT03302403, NCT03380039, NCT03716856), 24 patients received a dose ranging from 0.5 to 1.8 × 10^6 CT053 cells, the ORR was 87.5%, indicating a high rate of response to CT053 treatment, with 79.2% patients achieved CR (12.5%) or sCR (66.7%), demonstrating deep and durable responses, and the median follow-up time was 17.4 months, the mPFS was 18.8 months and the mDOR was 21.”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [250]
Anti-drug antibody was not detected in patients after CT053 infusion.
“Anti-drug antibody (ADA) was not detected in patients after infusion, suggesting no significant immunogenicity associated with CT053 treatment, and CT053 demonstrated strong efficacy and a good safety profile for patients with RRMM [250].”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [250]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · cited 3×
“Nevertheless, we observed little difference in CAR-T-cell expansion and persistence between CT053 and non-human BCMA CAR-T cells.(3) Antidrug antibody (ADA) was not detected in patients after infusion, demonstrating no obvious immunogenicity for CT053.”
BackgroundResultInfluentialB cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Krönke, J., Facon, T., Salnikov, A. V., Lesley, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02657 · Cited by 304
Flagged first, then by citations
Research works printed but not linked: 10
- Brudno JN, Maric I, Hartman SD. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018; 36(22):2267-2280. · DOI
- Xu J, Chen LJ, Yang SS. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci U S A. 2019; 116(19):9543-9551. · DOI
- Kumar S, Paiva B, Anderson KC. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016; 17(8):e328-e346.
- Hudecek M, Lupo-Stanghellini MT, Kosasih PL. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res. 2013; 19(12):3153-3164. · DOI
- Liu X, Jiang S, Fang C. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 2015; 75(17):3596-3607. · DOI
- Smith EL, Staehr M, Masakayan R. Development and evaluation of an optimal human single-chain variable fragment-derived BCMA-targeted CAR T cell vector. Mol Ther. 2018; 26(6):1447-1456. · DOI
- Gust J, Hay KA, Hanafi LA. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017; 7(12):1404-1419. · DOI · Paper page
- Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos MV, Miguel JS. Defining and treating high-risk multiple myeloma. Leukemia. 2015; 29(11):2119-2125. · DOI
- Zhao WH, Liu J, Wang BY. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018; 11(1):141. · DOI
- Yan Z, Cao J, Cheng H. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019; 6(10):e521-e529. · DOI
Cited by
Sorted by citations
Multiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Metadata
- Authors
- Yang, M., Zhang, W., Yu, K., Wang, P., Jiang, H., Chen, L., Meng, H., Weng, Y., Tao, R., Huang, X., Xing, C., Wang, H., Wan, J., Wang, S., Dai, L., Hendrix, A. Y., Xiao, J., Wang, W., Ma, H., Hao, S., Jin, J., Li, Z., & Jiang, S.
- Affiliations
- First Affiliated Hospital Zhejiang University (CN)
- Shanghai Jiao Tong University (CN)
- Wenzhou Medical University (CN)
- Corresponding author
- Yang, Min
- Zhang, Wenhao
- Yu, Kang
- Wang, Peng
- Jiang, Hua
- Hao, Siguo
- Jin, Jie
- Li, Zonghai
- Jiang, Songfu
- ORCID
- Venue
- Haematologica
- Published
- 2022-04-21
- Volume
- 107
- Issue
- 8
- Pages
- 1960-1965
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- PMC
- PMC9335117
- OpenAlex
- W4224241187
- Cited by
- 22
- References
- 3
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 6 · 2023: 1 · 2022: 2
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Haematologica (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- BCMA, CAR T-cell therapy, scFv, relapsed/refractory multiple myeloma, bispecific T-cell engagers
- MeSH terms
- Receptors, Chimeric Antigen, Humans, Multiple Myeloma, Immunotherapy, Adoptive, Clinical Trials, Phase I as Topic, B-Cell Maturation Antigen, Neoplasms, Plasma Cell, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
